

Product datasheet for **TG305626**

Caveolin 3 (CAV3) Human shRNA Plasmid Kit (Locus ID 859)

Product data:

| | |
|---------------------------|---|
| Product Type: | shRNA Plasmids |
| Product Name: | Caveolin 3 (CAV3) Human shRNA Plasmid Kit (Locus ID 859) |
| Locus ID: | 859 |
| Synonyms: | LGMD1C; LQT9; MPDT; RMD2; VIP-21; VIP21 |
| Vector: | pGFP-V-RS (TR30007) |
| E. coli Selection: | Kanamycin |
| Mammalian Cell Selection: | Puromycin |
| Format: | Retroviral plasmids |
| Components: | CAV3 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 859). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
| RefSeq: | NM_001234 , NM_033337 , NM_001234.1 , NM_001234.2 , NM_001234.3 , NM_001234.4 , NM_033337.1 , NM_033337.2 , BC069368 , BC102036 , BC102033 , BC102037 , NM_033337.3 , NM_001234.5 |
| UniProt ID: | P56539 |
| Summary: | This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intracellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites. [provided by RefSeq, Jul 2008] |
| shRNA Design: | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service . |



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).